11/19
10:51 am
rlay
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround [Yahoo! Finance]
Low
Report
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround [Yahoo! Finance]
11/8
02:32 pm
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.
11/7
04:05 pm
rlay
Relay Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Relay Therapeutics to Participate in Upcoming Investor Conferences
11/6
04:22 pm
rlay
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
Low
Report
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
11/6
04:05 pm
rlay
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Low
Report
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
10/30
04:05 pm
rlay
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
Low
Report
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
10/28
10:21 am
rlay
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses [Yahoo! Finance]
Low
Report
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses [Yahoo! Finance]
10/14
08:41 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
9/17
01:05 pm
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock.
9/16
05:48 pm
rlay
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion [Seeking Alpha]
Medium
Report
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion [Seeking Alpha]
9/16
09:13 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $28.00 price target on the stock.
Low
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $28.00 price target on the stock.
9/16
08:03 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $18.00 to $19.00. They now have a "buy" rating on the stock.
Low
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $18.00 to $19.00. They now have a "buy" rating on the stock.
9/11
08:23 am
rlay
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Ka Mutations [Seeking Alpha]
High
Report
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Ka Mutations [Seeking Alpha]
9/10
08:28 pm
rlay
Relay Therapeutics Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
High
Report
Relay Therapeutics Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
9/10
08:21 pm
rlay
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
High
Report
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
9/10
12:09 pm
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at Bank of America Co. from $20.00 to $24.00. They now have a "buy" rating on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at Bank of America Co. from $20.00 to $24.00. They now have a "buy" rating on the stock.
9/10
11:15 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at Barclays PLC from $14.00 to $17.00. They now have an "overweight" rating on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at Barclays PLC from $14.00 to $17.00. They now have an "overweight" rating on the stock.
9/10
11:15 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at JPMorgan Chase & Co. from $23.00 to $21.00. They now have an "overweight" rating on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at JPMorgan Chase & Co. from $23.00 to $21.00. They now have an "overweight" rating on the stock.
9/10
09:02 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $20.00 price target on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $20.00 price target on the stock.
9/10
07:59 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) was downgraded by analysts at Oppenheimer Holdings Inc. from an "outperform" rating to a "market perform" rating.
9/10
07:59 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock, up previously from $10.60.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock, up previously from $10.60.
9/9
05:07 pm
rlay
Relay Therapeutics announces proposed public offering of common stock [Seeking Alpha]
Low
Report
Relay Therapeutics announces proposed public offering of common stock [Seeking Alpha]
9/9
04:34 pm
rlay
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Relay Therapeutics Announces Proposed Public Offering of Common Stock
9/9
07:00 am
rlay
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival [Yahoo! Finance]
High
Report
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival [Yahoo! Finance]
9/9
06:55 am
rlay
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
High
Report
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival